[PDF][PDF] Second-line treatment of advanced NSCLC: Comparison of efficacy of erlotinib and chemotherapy
O Fiala, M Pesek, J Finek, J Krejci, Z Bortlicek… - Neoplasma, 2013 - researchgate.net
Results of analysis show that even patients without EGFR mutation are able to benefit from
erlotinib treatment in the second line. The efficacy (DCR, PFS) of erlotinib in patients without …
erlotinib treatment in the second line. The efficacy (DCR, PFS) of erlotinib in patients without …
[PDF][PDF] The efficacy and safety of erlotinib compared with chemotherapy in previously treated NSCLC: A meta-analysis
FZ Wu, JJ Song, ZW Zhao, X Huang, J Mao, J Tu… - Math Biosci …, 2019 - aimspress.com
Background: An increasing number of patients with advanced non-small cell lung cancer
(NSCLC) have a poor prognosis and develop progressive disease after receiving …
(NSCLC) have a poor prognosis and develop progressive disease after receiving …
Retreatment with erlotinib: regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment
A Becker, L Crombag, DAM Heideman… - European journal of …, 2011 - Elsevier
BACKGROUND: Tyrosine kinase inhibitors (TKI) of the epidermal growth factor receptor
(EGFR) are approved as treatment of non-small-cell lung cancer (NSCLC). Despite an …
(EGFR) are approved as treatment of non-small-cell lung cancer (NSCLC). Despite an …
[HTML][HTML] Predictive and prognostic factors in second-and third-line erlotinib treatment in NSCLC patients with known status of the EGFR gene
P Krawczyk, DM Kowalski… - Oncology …, 2013 - spandidos-publications.com
Erlotinib is a reversible tyrosine kinase inhibitor of epidermal growth factor receptor (TKI
EGFR). In Poland, as of July 2012, it is used in the treatment only of patients with non-small …
EGFR). In Poland, as of July 2012, it is used in the treatment only of patients with non-small …
Use of erlotinib or gefitinib as initial therapy in advanced NSCLC
GR Oxnard, VA Miller - Oncology, 2010 - search.proquest.com
Tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor receptor (EGFR), such
as erlotinib (Tarceva) and gefitinib (Iressa), have shown remarkable activity in a portion of …
as erlotinib (Tarceva) and gefitinib (Iressa), have shown remarkable activity in a portion of …
Erlotinib and concurrent chemoradiation in pretreated NSCLC patients: radiobiological basis and clinical results
S Ramella, AM Alberti, E Cammilluzzi… - BioMed Research …, 2013 - Wiley Online Library
Aims. To establish feasibility of the combination of Erlotinib and concurrent chemoradiation
in pre‐treated patients with locally advanced or metastatic NSCLC. Materials and Methods …
in pre‐treated patients with locally advanced or metastatic NSCLC. Materials and Methods …
NEJ026: phase III study comparing bevacizumab plus erlotinib to erlotinib in patients with untreated NSCLC harboring activating EGFR mutations
M Maemondo, T Fukuhara, S Sugawara… - Annals of …, 2016 - annalsofoncology.org
Background Development of treatment for EGFR-mutated non-small-cell lung cancer
(NSCLC) had been focused on monotherapy of gefitinib, erlotinib, or afatinib. However …
(NSCLC) had been focused on monotherapy of gefitinib, erlotinib, or afatinib. However …
Chemotherapy with erlotinib or chemotherapy alone in advanced NSCLC with acquired resistance to EGFR tyrosine kinase inhibitors (TKI).
SB Goldberg, GR Oxnard, S Digumarthy, A Muzikansky… - 2012 - ascopubs.org
7524 Background: EGFR-mutant NSCLC has an oncogene-addicted phenotype that confers
sensitivity to EGFR TKIs. Prior data suggests EGFR addiction persists after development of …
sensitivity to EGFR TKIs. Prior data suggests EGFR addiction persists after development of …
Treatment on advanced NSCLC: platinum-based chemotherapy plus erlotinib or platinum-based chemotherapy alone? A systematic review and meta-analysis of …
We performed a systematic review and meta-analysis to assess the potential of erlotinib plus
platinum-based chemotherapy relative to platinum-based chemotherapy alone for advanced …
platinum-based chemotherapy relative to platinum-based chemotherapy alone for advanced …
[HTML][HTML] A phase II study of erlotinib as first-line treatment in Japanese advanced NSCLC patients harboring EGFR mutations
A Horiike, M Nishio, K Goto, N Yamamoto… - Annals of …, 2012 - Elsevier
Background Several studies of EGFR TKIs have shown a benefit in response and
progression-free survival (PFS) for NSCLC patients harboring EGFR mutations in the first …
progression-free survival (PFS) for NSCLC patients harboring EGFR mutations in the first …